Hemopure for life-threatening anemia when blood transfusions aren’t an option
Part of Blood & lymphatic clinical trials.
This study offers HBOC-201 (Hemopure), a type of blood substitute made from bovine (beef) hemoglobin, to treat severe, life-threatening anemia. It’s meant for adults who have very low hemoglobin with serious signs of poor oxygen delivery, and who can’t (or don’t qualify) for standard blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your hemoglobin is 8 g/dL or lower, and you have active serious illness from low oxygen (for example, active bleeding, heart strain, confusion, kidney failure, or high lactic acid).
- You (or your legal health decision-maker) must be able and willing to sign informed consent.
- You cannot have a known severe allergy to beef products.
- You likely cannot join if you have uncontrolled high blood pressure, certain serious heart or kidney problems that aren’t controlled, too much fluid in the blood, or a mast cell condition called systemic mastocytosis.
- You likely cannot join if you are over 80 years old, or if doctors think you can receive regular blood transfusions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving blood in a personalized way, instead of a standard approach, is better for people on a heart-lung bypass machine (VA-ECMO) for heart-related shock. It may help find a safer blood transfusion strategy while you are critically ill.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
This study tests whether giving blood transfusions based on each patient's needs during and after heart surgery is safe and effective. It compares different transfusion thresholds to see which works better.
This trial tests a special way of preparing red blood cells for transfusion to see if it can help people with sickle cell anemia. If you already get regular transfusions, this study might offer a new option that could reduce complications.
This trial looks at how to treat a severe, whole-body immune overreaction (“hemophagocytosis”) in adults who are critically ill. You might be considered if blood counts are low (white blood cells and platelets) and if you are already receiving a growth-factor medicine (rhG-CSF).
This study tests an oral medication (MY008211A) designed to reduce red blood cell destruction in people with paroxysmal nocturnal hemoglobinuria (PNH). The trial aims to see if the drug is safe and effective in improving anemia and lowering markers of disease activity.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.